GlassScriptPhysician profile
Matthew A Cring
NPI 1073567103
$336.32
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $336.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $67.09 | 2021 | |
| Pfizer INC. | $55.35 | 2021 | |
| Eisai INC. | $26.59 | 2021 | |
| Exelixis INC. | $24.40 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $21.85 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $20.06 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $19.44 | 2021 | |
| Puma Biotechnology, INC. | $18.85 | 2021 | |
| Dova Pharmaceuticals | $16.90 | 2021 | |
| Epizyme, INC. | $14.82 | 2021 | |
| Seagen INC. | $13.95 | 2021 | |
| Lilly USA, LLC | $13.28 | 2021 | |
| Emd Serono, INC. | $12.21 | 2021 | |
| Glaxosmithkline, LLC. | $11.53 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Cring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.